In the pharmaceutical industry, the incorporation of the disciplines of drug metabolism and pharmacokinetics (DMPK), and pharmacodynamics (PD) into various drug development process has been recognized to be extremely important for appropriate compound selection and optimization. During drug discovery and development, the identification of the critical DMPK/PD issues of new compounds plays an essential role in understanding their pharmacological profiles, structure-activity relationships, toxicology, clinical trial design and so on. Characterization of absorption, distribution, metabolism, and excretion (ADME) profiles are a critical step in drug research and development. Pharmaceutical and biotechnology companies often outsource a large number of compounds to Contract Research Organization (CRO) to screen their DMPK and ADME properties in a time and cost effective manner.
Alliance Pharma, Inc., is a Contract Research Organization (CRO) providing in vitro and in vivo ADME and DMPK support for drug discovery and development for the pharmaceutical and biotechnology industries. Our Drug Metabolism Department have tested thousands of compounds in a broad range of in vitro and in vivo systems for DMPK studies, in a variety of species (mouse, rat, dog, monkey, human, etc.). Our expertise has been demonstrated in a wide range of study types, including cell permeability and transporters (Caco-2 and MDR1-MDCK), aqueous solubility, protein binding in plasma and blood, metabolic stability (intrinsic clearance), direct and time-dependent CYP inhibition, CYP induction, drug-drug interaction (DDI), reaction phenotyping, metabolite identification and profiling, in vitro species comparisons for preclinical animal model, in vivo animal PK. Our team is fully trained in GLP and GCP regulations and using only the state-of-the-art instrumentations and most updated methods to conduct studies with significant cost savings to clients.
